NCT01905436View on ClinicalTrials.gov

Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia

CompletedOBSERVATIONAL
Enrollment

21,862

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

April 30, 2017

Study Completion Date

July 31, 2021

Conditions
Lymphatic FilariasisOnchocerciasisSoil Transmitted Helminth (STH) Infections
Interventions
DRUG

Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration

Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.

Trial Locations (1)

Unknown

Liberian Institute of Biomedical Research, Charlesville

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT01905436 - Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia | Biotech Hunter | Biotech Hunter